Trial reportBMC psychiatry2025
The effect of Lactobacillus casei on postpartum depression: a randomized controlled trial.
Trial report in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe growing evidence of the bidirectional relationship between gut microbial flora and brain neurochemistry and consequently behavior, has recently garnered significant attention as the gut-brain microbial axis. Considering the conflicting results of trials investigating the effects of probiotic therapy on depression, the present study aims to evaluate the impact of Lactobacillus casei on postpartum depression.
methodThis randomized controlled trial was conducted on 74 postpartum women admitted to Al-Zahra Hospital, Tabriz, Iran. Eligible women were randomly assigned into the intervention and placebo groups using block randomization method. The intervention group received 500 mg of capsules containing Lactobacillus casei 431 at a dose of 1.5 × 109 cfu/ml once daily, starting the day after delivery and continuing until 21 ± 1 days postpartum. Depression levels were assessed at 5 ± 1, 15 ± 1, and 21 ± 1 days after delivery using independent t-tests and RMANOVA.
resultsThe mean depression score (SD) at 5 ± 1 days postpartum was 4.7 (2.5) in the probiotic group and 5.6 (2.4) in the placebo group. By 15 ± 1 days postpartum, the scores increased to 9.28 (1.68) in the probiotic group and 11.57 (2.55) in the placebo group. At 21 ± 1 days postpartum, the mean depression scores were 7.39 (2.96) and 8.11 (3.61) in the probiotic and placebo groups, respectively. No significant difference was observed between the groups (Mean Difference: -1.68, 95% CI: 0.08 to -2.56 to, p = 0.71).
conclusionLactobacillus casei had no significant effect on alleviating postpartum depression symptoms. Further studies should focus on starting probiotic in pregnant women for a longer duration of use. CLINICAL TRIAL NUMBER: Iranian Registery of Clinical Trials-Beta vertion, https://irct.behdasht.gov.ir/trial/71775 (IRCT20170506033834N7), registered 2021-08-11.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.